Literature DB >> 19457691

Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion.

Emmanuelle Dernis1, Frédéric Lavie, Carine Salliot, René-Marc Flipo, Alain Saraux, Jean-Francis Maillefert, Carle Paul, Philippe Goupille, Alain Cantagrel, Pascal Claudepierre, Philippe Gaudin, Jacques Tebib, Daniel Wendling, Thierry Schaeverbeke, Xavier Le Loët, Bernard Combe.   

Abstract

OBJECTIVES: To develop recommendations about treatment (except anti-TNF agents) of psoriatic arthritis with peripheral joint involvement (PsA) seen in everyday practice, using evidence from the literature, supplemented with expert opinion when needed.
METHODS: The recommendations were based on evidence from the literature. First, a scientific committee used a Delphi procedure to select five focal points of interest. Then, a literature task force looked for relevant publications in the following: Cochrane, Pubmed, and Ovid databases and abstracts from the French Society for Rheumatology, European League against Rheumatism and American College of Rheumatology. Based on the data from these publications, recommendations were drafted and then validated by a group of 68 experts. The strength of each recommendation was determined, as well as the extent of agreement among the experts.
RESULTS: The evidence extracted from 73 selected papers was presented to experts during interactive workshops. At the end of the workshops, the experts drafted six recommendations, which were then validated by a final vote including all participants. These six recommendations displayed various strength from B to D.
CONCLUSION: These recommendations should help to improve practice uniformity and, ultimately, to improve the management of PsA in France.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457691     DOI: 10.1016/j.jbspin.2009.03.002

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  3 in total

1.  A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.

Authors:  Gabrielle H Kingsley; Anna Kowalczyk; Helen Taylor; Fowzia Ibrahim; Jonathan C Packham; Neil J McHugh; Diarmuid M Mulherin; George D Kitas; Kuntal Chakravarty; Brian D M Tom; Aidan G O'Keeffe; Peter J Maddison; David L Scott
Journal:  Rheumatology (Oxford)       Date:  2012-02-17       Impact factor: 7.580

2.  Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis.

Authors:  Filomena Morisco; Maria Guarino; Serena La Bella; Luisa Di Costanzo; Nicola Caporaso; Fabio Ayala; Nicola Balato
Journal:  BMC Gastroenterol       Date:  2014-12-19       Impact factor: 3.067

3.  Relationship Between Interleukin-6 -174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients.

Authors:  Renata Sokolik; Milena Iwaszko; Jerzy Świerkot; Barbara Wysoczańska; Lucyna Korman; Piotr Wiland; Katarzyna Bogunia-Kubik
Journal:  Pharmgenomics Pers Med       Date:  2021-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.